Researchers identify early biomarkers for Alzheimer's and ALS

Researchers have identified a potential early biomarker for Alzheimer's disease in individuals with Down syndrome. A study conducted by IR Sant Pau, in collaboration with Martin Luther University in Germany and the German Center for Neurodegenerative Diseases, found that levels of beta-synuclein—a protein related to synaptic function—begin to rise in the third decade of life. This elevation occurs approximately 21 years before the average age of diagnosis for prodromal Alzheimer's in the studied cohort, offering a window for much earlier detection of synaptic failure.

In a separate area of neurodegenerative research, scientists at the X International ALS Meeting in Spain discussed the origins of Amyotrophic Lateral Sclerosis (ALS). Researchers are investigating whether the disease begins in motor neurons, muscles, or other components. Identifying the earliest biological event in ALS is considered critical for developing targeted biomarkers and therapies to combat the progressive degeneration of motor neurons.